Drug Trial Radar · NCT05653271
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 21, 2023
Primary completion
Mar 31, 2026
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- Acepodia Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.
Conditions
- B-cell Lymphoma
- Non Hodgkin Lymphoma
- DLBCL
- Primary Mediastinal Large B Cell Lymphoma
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Burkitt Lymphoma
- High-grade B-cell Lymphoma
Interventions
CyclophosphamideDrug
Lymphodepleting agent
FludarabineDrug
Lymphodepleting agent
ACE1831Drug
Allogeneic gamma delta T (gdT) cell therapy
ObinutuzumabDrug
Anti-CD20 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs), Dose Limiting Toxicities (DLTs), adverse events of special interest (AESIs), and serious adverse events (SAEs)Time frame: 2 years
- Change from baseline in ECOG statusTime frame: 1 year
- Change from baseline in physical examination resultsTime frame: 1 year
- Change from baseline clinical laboratory tests resultsTime frame: 1 year
- Change from baseline in urinalysis resultsTime frame: 1 year
- Change from baseline in vital signs resultsTime frame: 1 year
- Change from baseline in electrocardiogram (ECG) resultsTime frame: 1 month
- Maximum Tolerated Dose (MTD)Time frame: 1 month
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
AdventHealth Orlando
Orlando, Florida
Emory University
Atlanta, Georgia
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana
Norton Cancer Institute
Louisville, Kentucky
The University of Texas MD Anderson Cancer Center
Houston, Texas
Queen Mary Hospital
Hong Kong, Hong Kong, Hong Kong
Tamsui MacKay Memorial Hospital
New Taipei City, Taiwan
Linkou Chang-Gung Memorial Hospital
Taoyuan City, Taiwan
Kaohsiung Chang-Gung Memorial Hospital
Kaohsiung City, Kaohsiung, Taiwan
National Cheng Kung University Hospital
Tainan, Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taipei, Taiwan
Ministry of Health and Welfare Shuang-Ho Hospital
New Taipei City, Taiwan, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.